Ocuphire Pharma Investor Day Presentation Deck

DR DME 11 Ų APX3330 Chemistry and MOA Presented by: Mark Kelley, PhD INDIANA UNIVERSITY MELVIN AND BREN SIMON CANCER CENTER Mark Kelley, PhD Louisiana State University ● ● Ocuphire PHARMA Chief Scientific Officer and Founder of Apexian Pharmaceuticals Discovered and has developed the redox-specific inhibitors of Ref-1 for over 20 years Associate Director of Basic Science at Indiana University Simon Comprehensive Cancer Center Betty and Earl Herr Professor of Pediatric Oncology Research, Indiana University Fellow, American Association for the Advancement of Science

View entire presentation